Abstract | BACKGROUND: MATERIALS AND METHODS: A prospective, observational study was conducted in the general ICU of Guangdong Provincial People's Hospital. Seventeen serum or urine biomarkers were studied for their abilities alone or in combination for predicting AKI and severe AKI. RESULTS: Of 1498 patients, 376 (25.1%) developed AKI. Serum cystatin C (CysC) showed the best performance for predicting both AKI (area under the receiver operator characteristic curve [AUC] = 0.785, mean square error [MSE] = 0.118) and severe AKI (AUC = 0.883, MSE = 0.06). Regarding biomarkers combinations, CysC plus N-acetyl-β-d- glucosaminidase-to- creatinine ratio (NAG/Cr) was the best for predicting AKI (AUC = 0.856, MSE = 0.21). At the same time, CysC plus lactic acid (LAC) performed the best for predicting severe AKI (AUC = 0.907, MSE = 0.058). Regarding combinations of biomarkers and clinical markers, CysC plus Acute Physiology and Chronic Health Evaluation (APACHE) II score showed the best performance for predicting AKI (AUC = 0.868, MSE = 0.407). In contrast, CysC plus Multiple Organ Dysfunction Score ( MODS) had the highest predictive ability for severe AKI (AUC = 0.912, MSE = 0.488). CONCLUSION: Apart from CysC, the combination of most clinically available biomarkers or clinical markers does not significantly improve the forecasting ability, and the cost-benefit ratio is not economical.
|
Authors | Yating Hou, Yujun Deng, Linhui Hu, Linling He, Fen Yao, Yifan Wang, Jia Deng, Jing Xu, Yirong Wang, Feng Xu, Chunbo Chen |
Journal | Journal of translational internal medicine
(J Transl Int Med)
Vol. 9
Issue 4
Pg. 273-284
(Dec 01 2021)
ISSN: 2450-131X [Print] Poland |
PMID | 35136726
(Publication Type: Journal Article)
|
Copyright | © 2021 Yating Hou et al., published by Sciendo. |